KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Deferred Tax: 2020-2024

Historic Long-Term Deferred Tax for Pacira BioSciences (PCRX) over the last 5 years, with Dec 2024 value amounting to $130.4 million.

  • Pacira BioSciences' Long-Term Deferred Tax fell 10.32% to $120.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year decrease of 10.32%. This contributed to the annual value of $130.4 million for FY2024, which is 9.77% down from last year.
  • As of FY2024, Pacira BioSciences' Long-Term Deferred Tax stood at $130.4 million, which was down 9.77% from $144.5 million recorded in FY2023.
  • Pacira BioSciences' Long-Term Deferred Tax's 5-year high stood at $160.3 million during FY2022, with a 5-year trough of $106.2 million in FY2020.
  • Its 3-year average for Long-Term Deferred Tax is $145.1 million, with a median of $144.5 million in 2023.
  • In the last 5 years, Pacira BioSciences' Long-Term Deferred Tax soared by 44.46% in 2021 and then declined by 9.87% in 2023.
  • Over the past 5 years, Pacira BioSciences' Long-Term Deferred Tax (Yearly) stood at $106.2 million in 2020, then skyrocketed by 44.46% to $153.4 million in 2021, then grew by 4.53% to $160.3 million in 2022, then declined by 9.87% to $144.5 million in 2023, then decreased by 9.77% to $130.4 million in 2024.